A third of tomorrow's molecules will come from China. Just ten years ago, that figure was three percent. The entire healthcare ecosystem has shifted from a massive potential market into a testing ground for rapid, decentralized execution.The questions goes beyond how to enter this system, but how to keep pace with its relentless evolution.

Welcome to Pharma Minds, Summer Series "Executing differently takes courage". I placed this conversation with Guillaume Delmotte in the second position of our series because he brings something the other episodes simply do not have: a systemic reading of execution. In China, execution is not an individual choice but a mode of operation for the state, highly centralized in its objectives and completely decentralized in its application. I chose this discussion to explore what it concretely costs to actually do what you said you would do at a massive, systemic scale. It reveals that large-scale delivery is only possible when partnerships are built for the long term and when you accept that constant adaptation becomes the course itself. 

Guillaume Delmotte spent twenty years within Ipsen, navigating international leadership roles across Europe, Russia, and most recently China. Operating in a highly fluid, fiercely competitive market of 1.4 billion people, his impossible context was learning to execute without a rigid playbook. He had to navigate the immense tension between capturing an unprecedented volume opportunity and facing brutal price pressures, all while reinventing patient pathways from the ground up alongside local players.

In this episode, we cover:

◾️Geography Commands Strategy : Why adapting tactics to localized provincial health policies is the only way to scale.

◾️The Virtual Hospital Shift : How digitized care pathways and AI are managing patient flows for minor and severe pathologies.

◾️Breaking the Pricing Rules : Moving away from rigid formulation constraints to establish entirely new value models.

◾️Building True Ecosystems : Leveraging local distributors and pharmacy data mining to find undiagnosed rare disease patients.

◾️The Innovation Mirage : Balancing incredible volume potential with aggressive price cuts and volume-based procurement.

The final objective remains clear. The path to get there changes every single day. Those who stop moving lose the market. 

👉 What element of the Chinese execution model do you think European pharma should adopt first? Let us know in the comments. 

Ambition sets the target. Local context dictates the path.

If you want to follow the whole series, don't forget to subscribe.

-

This episode has been translated with the help of AI tools and edited to align with the editorial direction of this series. 

Originally released on: 12/01/2026.

To listen to the original French version of this episode: https://smartlink.ausha.co/pharma-minds/49-du-chaos-au-futur-les-lecons-d-un-leader-pharma-en-chine.

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.